{"id":"clascoterone-5-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clascoterone selectively inhibits androgen receptor activity in sebaceous glands and skin, thereby reducing sebum production and the proliferation of acne-causing bacteria. By acting as a topical antiandrogen, it addresses one of the key pathogenic factors in acne without systemic hormonal effects. This mechanism makes it particularly useful for acne patients who cannot tolerate or do not respond to conventional treatments.","oneSentence":"Clascoterone is an androgen receptor antagonist that blocks androgen signaling in skin to reduce sebum production and acne lesions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:18.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT05910450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cassiopea SpA","startDate":"2023-06-21","conditions":"Alopecia, Androgenetic","enrollment":703},{"nctId":"NCT05914805","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)","status":"COMPLETED","sponsor":"Cassiopea SpA","startDate":"2023-08-17","conditions":"Alopecia, Androgenetic","enrollment":762},{"nctId":"NCT02279823","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Intrepid Therapeutics, Inc.","startDate":"2014-10","conditions":"Androgenetic Alopecia","enrollment":95}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CB-03-01 5% solution"],"phase":"phase_3","status":"active","brandName":"Clascoterone 5% solution","genericName":"Clascoterone 5% solution","companyName":"Cassiopea SpA","companyId":"cassiopea-spa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clascoterone is an androgen receptor antagonist that blocks androgen signaling in skin to reduce sebum production and acne lesions. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}